Sarda Proteins（519242）株式概要Sarda Proteins Ltd.はインドで食用油と農業関連商品を取り扱っている。 詳細519242 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績4/6財務の健全性3/6配当金0/6報酬今年は黒字化を達成 リスク分析意味のある時価総額がありません ( ₹921M )株式の流動性は非常に低い 過去1年間で株主の希薄化は大幅に進んだ 意味のある収益がありません ( ₹182M )すべてのリスクチェックを見る519242 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW464,325 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA464,325 investors already sharing narrativesYour Fair Value₹Current Price₹102.6679.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4m676m2016201920222025202620282031Revenue ₹675.6mEarnings ₹103.6mAdvancedSet Fair ValueView all narrativesSarda Proteins Ltd 競合他社MRP AgroSymbol: BSE:543262Market cap: ₹1.0bVistar AmarSymbol: BSE:538565Market cap: ₹1.2bChandrima MercantilesSymbol: BSE:540829Market cap: ₹2.1bAdon Agro CommoditiesSymbol: BSE:544809Market cap: ₹2.0b価格と性能株価の高値、安値、推移の概要Sarda Proteins過去の株価現在の株価₹102.6652週高値₹144.3052週安値₹59.95ベータ-2.561ヶ月の変化4.99%3ヶ月変化15.74%1年変化-28.86%3年間の変化128.13%5年間の変化128.13%IPOからの変化914.43%最新ニュースお知らせ • Aug 08Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million.Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Rights Offeringお知らせ • Jul 31+ 1 more updateSarda Proteins Limited Announces Management ChangesSarda Proteins Limited held an Extra Ordinary General Meeting on July 30, 2026. The company passed resolutions for the regularization of Mr. Gunvantray Jayantilal Zaladi (DIN: 11253353) as Non-Executive and Non-Independent Director, regularization of Mr. Shivam Gunvantray Zaladi (DIN: 11251860) as Non-Executive and Non-Independent Director, regularization of Mr. Yagnik Satasiya as Non-Executive Chairperson, and appointment of Ms. Minal Surendra Jain (DIN: 11822395) as Woman Independent Director.Reported Earnings • Jul 18First quarter 2027 earnings released: EPS: ₹1.85 (vs ₹2.86 loss in 1Q 2026)First quarter 2027 results: EPS: ₹1.85 (up from ₹2.86 loss in 1Q 2026). Revenue: ₹184.7m (up 69% from 1Q 2026). Net income: ₹16.6m (up ₹21.5m from 1Q 2026). Profit margin: 9.0% (up from net loss in 1Q 2026). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).最新情報をもっと見るRecent updatesお知らせ • Aug 08Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million.Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Rights Offeringお知らせ • Jul 31+ 1 more updateSarda Proteins Limited Announces Management ChangesSarda Proteins Limited held an Extra Ordinary General Meeting on July 30, 2026. The company passed resolutions for the regularization of Mr. Gunvantray Jayantilal Zaladi (DIN: 11253353) as Non-Executive and Non-Independent Director, regularization of Mr. Shivam Gunvantray Zaladi (DIN: 11251860) as Non-Executive and Non-Independent Director, regularization of Mr. Yagnik Satasiya as Non-Executive Chairperson, and appointment of Ms. Minal Surendra Jain (DIN: 11822395) as Woman Independent Director.Reported Earnings • Jul 18First quarter 2027 earnings released: EPS: ₹1.85 (vs ₹2.86 loss in 1Q 2026)First quarter 2027 results: EPS: ₹1.85 (up from ₹2.86 loss in 1Q 2026). Revenue: ₹184.7m (up 69% from 1Q 2026). Net income: ₹16.6m (up ₹21.5m from 1Q 2026). Profit margin: 9.0% (up from net loss in 1Q 2026). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 420% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹722.2m market cap, or US$7.72m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).お知らせ • Feb 10Sarda Proteins Ltd to Report Q3, 2026 Results on Feb 14, 2026Sarda Proteins Ltd announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026Board Change • Jan 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). MD & Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Nov 05Sarda Proteins Ltd to Report Q2, 2026 Results on Nov 14, 2025Sarda Proteins Ltd announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Aug 12Sarda Proteins Ltd to Report Q1, 2026 Results on Aug 14, 2025Sarda Proteins Ltd announced that they will report Q1, 2026 results on Aug 14, 2025Board Change • Aug 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jul 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jun 23Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jun 02Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • May 19Full year 2025 earnings released: EPS: ₹0.03 (vs ₹0.11 in FY 2024)Full year 2025 results: EPS: ₹0.03 (down from ₹0.11 in FY 2024). Revenue: ₹241.9m (up ₹229.0m from FY 2024). Net income: ₹51.0k (down 74% from FY 2024). Profit margin: 0% (down from 1.5% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 156 percentage points per year, which is a significant difference in performance.お知らせ • May 13Sarda Proteins Ltd to Report Q4, 2025 Results on May 15, 2025Sarda Proteins Ltd announced that they will report Q4, 2025 results on May 15, 2025New Risk • Mar 20New major risk - Revenue and earnings growthEarnings have declined by 5.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 5.2% per year over the past 5 years. Market cap is less than US$10m (₹215.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹241m revenue, or US$2.8m).Board Change • Mar 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 13Sarda Proteins Ltd to Report Q3, 2025 Results on Jan 17, 2025Sarda Proteins Ltd announced that they will report Q3, 2025 results on Jan 17, 2025お知らせ • Oct 26Sarda Proteins Ltd to Report Q2, 2025 Results on Nov 08, 2024Sarda Proteins Ltd announced that they will report Q2, 2025 results on Nov 08, 2024お知らせ • Sep 11Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024, at 16:00 Indian Standard Time.Reported Earnings • Aug 14First quarter 2025 earnings released: ₹0.46 loss per share (vs ₹0.01 loss in 1Q 2024)First quarter 2025 results: ₹0.46 loss per share (further deteriorated from ₹0.01 loss in 1Q 2024). Net loss: ₹801.0k (loss widened ₹776.0k from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings.お知らせ • Aug 10+ 1 more updateSarda Proteins Ltd Announces Resignation of Mahavir Pratap Sharma as Independent Director, Effective August 11, 2024Sarda Proteins Ltd. announced that the Company has received Resignation letter from Mr. Mahavir Pratap Sharma, Independent Director of the Company, informing about his resignation from the post of Independent Director of the Company due to some personal and unavoidable reason from the said position with effect from August 11, 2024.お知らせ • Jul 31+ 1 more updateSarda Proteins Ltd Receives Resignation from Amit Kumar Modi as Company Secretary & Compliance OfficerSarda Proteins Ltd. received Resignation letter dated 31 July, 2024 from Mr. Amit Kumar Modi, Company Secretary & Compliance Officer of the Company informing about his resignation from the post of Company Secretary & Compliance Officer of the Company due to some personal and unavoidable reason with effect from the closure of business hours of 31 July, 2024.お知らせ • Jul 17+ 1 more updateSarda Proteins Ltd Approves Board ChangesSarda Proteins Ltd. at its Board of Directors of the Company in their meeting held on 17 day of July, 2024, approved the resignation of Mrs. Vanita Bhanot from the post of Non-Executive Director, effective from July 17, 2024. The board further announced the appointment of Mr. Chintan Umeshbhai Bhatt as the Additional Director (Independent), Mr. Dhairyakumar Mohanbhai Thakkar as the Additional Director (Independent), Mrs. Dharaben Piyushkumar Patel, as the Additional Director (Non-Executive), effective from July 17, 2024. Mr. Chintan Umeshbhai Bhatt is Practicing Company Secretary. He is Associate memberof the Institute of Company Secretaries of India. He is Bachelor of Law (LL.B.), Commerce graduate (B.Com), Diploma in Tax Practice (DTP) and Diploma in Labour Practice (DLP) awarded by Gujarat University. He is having more than 4 years of experience in the field of Corporate Law and Advisory Services. Mr. Dhairyakumar Mohanbhai Thakkar is a Qualified Company Secretary from the Institute of Company Secretaries of India. He has an experience of more than 10 years in the field of Company Law matters and other corporate matters. Mrs. Dharaben Piyushkumar Patel is a commerce graduate with more than 10 years of experience in the business administration and business management. Terms of Appointment: To hold office till the upcoming Annual General Meeting of the company.お知らせ • Jul 15Sarda Proteins Ltd Announces Resignation of Shipra Gandhi as Chief Financial OfficerSarda Proteins Ltd. has received resignation letter dated 15t July, 2024 from Mrs. Shipra Gandhi, Chief Financial Officer (CFO) of the company informing about her resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from the closure of business hours of 15th July, 2024.お知らせ • Jun 25Sarda Proteins Ltd Appoints Khilan Hareshbhai Savaliya as Additional Director (Non-Executive)Sarda Proteins Ltd. at its board of directors meeting held on June 24, 2024, approved appointment of Mr. Khilan Hareshbhai Savaliya (DIN: 08790209) as the Additional Director (Non-Executive)' of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, with effect from 24th day of June, 2024. Terms of Appointment: To hold office till the ensuing Annual General Meetingof the company. With an experience of 3+ years in the field of Turnkey Project Management, Mr. Khilan Hareshbhai Savaliya brings a wealth of knowledge and productivity to the organization.Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Mahavir Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 31Sarda Proteins Ltd Appoints Chirag Shantilal Thumar as Additional Executive DirectorSarda Proteins Ltd. Board of Directors of the Company in meeting held on 28 day of May, 2024, approved the appointment of Mr. Chirag Shantilal Thumar as the Additional Director (Executive) of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, effective 28th May, 2024.Recent Insider Transactions • May 28MD & Director recently sold ₹3.0m worth of stockOn the 24th of May, Deepak Data sold around 35k shares on-market at roughly ₹84.58 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Deepak's only on-market trade for the last 12 months.Reported Earnings • May 02Full year 2024 earnings released: EPS: ₹0.11 (vs ₹0.19 loss in FY 2023)Full year 2024 results: EPS: ₹0.11 (up from ₹0.19 loss in FY 2023). Revenue: ₹14.6m (down 75% from FY 2023). Net income: ₹194.0k (up ₹524.3k from FY 2023). Profit margin: 1.3% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Apr 22Sarda Proteins Ltd to Report Q4, 2024 Results on Apr 30, 2024Sarda Proteins Ltd announced that they will report Q4, 2024 results on Apr 30, 2024Board Change • Feb 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.04 (vs ₹0.01 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.04 (up from ₹0.01 in 3Q 2023). Revenue: ₹10.4m (down 54% from 3Q 2023). Net income: ₹69.0k (up 306% from 3Q 2023). Profit margin: 0.7% (up from 0.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 06Sarda Proteins Ltd to Report Q3, 2024 Results on Feb 13, 2024Sarda Proteins Ltd announced that they will report Q3, 2024 results on Feb 13, 2024お知らせ • Nov 10Sarda Proteins Ltd Announces Resignation of Somya Data as Chief Financial OfficerSarda Proteins Ltd. announced that it has received Resignation letter dated 08t November, 2023. from. Mr. Somya Data, Chief Financial Officer (CFO) of the Company informing about his resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from closure of business hours of November 30, 2023.Reported Earnings • Nov 09Second quarter 2024 earnings released: ₹0.03 loss per share (vs ₹0.02 profit in 2Q 2023)Second quarter 2024 results: ₹0.03 loss per share (down from ₹0.02 profit in 2Q 2023). Revenue: ₹413.0k (down 99% from 2Q 2023). Net loss: ₹51.0k (down 289% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 31Sarda Proteins Ltd to Report Q2, 2024 Results on Nov 07, 2023Sarda Proteins Ltd announced that they will report Q2, 2024 results on Nov 07, 2023お知らせ • Aug 16Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.お知らせ • Aug 08Sarda Proteins Ltd to Report Q1, 2024 Results on Aug 14, 2023Sarda Proteins Ltd announced that they will report Q1, 2024 results on Aug 14, 2023New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹58m revenue, or US$706k). Market cap is less than US$10m (₹79.4m market cap, or US$967.3k). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).Reported Earnings • Jun 04Full year 2023 earnings released: ₹0.19 loss per share (vs ₹1.78 profit in FY 2022)Full year 2023 results: ₹0.19 loss per share (down from ₹1.78 profit in FY 2022). Revenue: ₹59.6m (down 45% from FY 2022). Net loss: ₹331.0k (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 24Sarda Proteins Ltd to Report Q4, 2023 Results on May 30, 2023Sarda Proteins Ltd announced that they will report Q4, 2023 results on May 30, 2023Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹55.35, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 91% over the past year.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹49.69, the stock trades at a trailing P/E ratio of 28.8x. Average trailing P/E is 30x in the Consumer Retailing industry in India. Total returns to shareholders of 51% over the past year.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹56.55, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 418% over the past three years.Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.32 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.01 (down from ₹0.32 in 3Q 2022). Revenue: ₹22.7m (down 17% from 3Q 2022). Net income: ₹17.0k (down 97% from 3Q 2022). Profit margin: 0.1% (down from 2.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 31Sarda Proteins Ltd Announces Chief Financial Officer ChangesBoard of Directors of the Sarda Proteins Ltd, at its meeting held on, 30th January, 2023 has appointed Mr. Somya Data as the Chief Financial Officer (CFO) of the Company with effect from 01st February, 2023. Reason for Change: Due to resignation tendered by Mr. Himanshu Gupta, the Board has decided to appoint Mr. Somya Data as the Chief Financial Officer (CFO) of the company. Date of Appointment: With effect from 01st February, 2023 Qualification and Professional Experience: He is a graduate in Commerce from University of Rajasthan and is also CMA-Inter qualified from the Institute of Cost Accountants of India. He hasimmense knowledge of Financial Planning, Management of Financial Risks, Book Keeping, Financial Reporting, Indian Accounting Standards and Cost Accounting Standards.お知らせ • Jan 24Sarda Proteins Ltd to Report Q3, 2023 Results on Jan 30, 2023Sarda Proteins Ltd announced that they will report Q3, 2023 results on Jan 30, 2023お知らせ • Jan 20Sarda Proteins Ltd Announces Resignation of Himanshu Gupta as Chief Financial Officer, Effective 30 January 2023Sarda Proteins Ltd. announced that the company has received resignation letter dated 19 January 2023 from Mr. Himanshu Gupta, chief financial officer (CFO) of the company informing about his resignation from the post of chief financial officer (CFO) due to some personal reasons with effect from closure of business hours of 30 January 2023.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹60.35, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 453% over the past three years.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹90.90, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 41x in the Consumer Retailing industry in India. Total returns to shareholders of 732% over the past three years.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹123, the stock trades at a trailing P/E ratio of 60.4x. Average trailing P/E is 45x in the Consumer Retailing industry in India. Total returns to shareholders of 1,029% over the past three years.Valuation Update With 7 Day Price Move • Nov 28Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹163, the stock trades at a trailing P/E ratio of 79.8x. Average trailing P/E is 37x in the Consumer Retailing industry in India. Total returns to shareholders of 1,390% over the past three years.Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.14 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.02 (up from ₹0.14 loss in 2Q 2022). Revenue: ₹27.9m (up 274% from 2Q 2022). Net income: ₹27.0k (up ₹266.0k from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 161% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 13Sarda Proteins Ltd to Report Q2, 2023 Results on Oct 19, 2022Sarda Proteins Ltd announced that they will report Q2, 2023 results on Oct 19, 2022Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.30, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 297% over the past three years.お知らせ • Aug 06Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022, at 12:30 Indian Standard Time.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹32.50, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 27x in the Consumer Retailing industry in India. Total returns to shareholders of 213% over the past three years.お知らせ • Jul 29Sarda Proteins Limited to Report Q1, 2023 Results on Aug 05, 2022Sarda Proteins Limited announced that they will report Q1, 2023 results on Aug 05, 2022Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹27.50, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 22x in the Consumer Retailing industry in India. Total returns to shareholders of 150% over the past three years.お知らせ • May 19Sarda Proteins Limited to Report Q4, 2022 Results on May 27, 2022Sarda Proteins Limited announced that they will report Q4, 2022 results on May 27, 2022Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.32 (up from ₹0.17 loss in 3Q 2021). Revenue: ₹27.4m (up 492% from 3Q 2021). Net income: ₹560.0k (up ₹854.0k from 3Q 2021). Profit margin: 2.0% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates.Board Change • Sep 17High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Jun 27Full year 2021 earnings released: ₹0.12 loss per share (vs ₹0.19 profit in FY 2020)The company reported a decent full year result with improved revenues, although earnings and control over costs were weaker. Full year 2021 results: Revenue: ₹114.4m (up 112% from FY 2020). Net loss: ₹202.0k (down 161% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹17.87, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 276% over the past three years.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹12.12, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 155% over the past three years.Reported Earnings • Feb 17Third quarter 2021 earnings released: ₹0.17 loss per share (vs ₹0.56 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹4.63m (down 67% from 3Q 2020). Net loss: ₹294.0k (down 131% from profit in 3Q 2020).お知らせ • Feb 04Sarda Proteins Ltd. to Report Q3, 2021 Results on Feb 12, 2021Sarda Proteins Ltd. announced that they will report Q3, 2021 results on Feb 12, 2021Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 16% share price gain to ₹10.00, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 23x. This compares to an average P/E of 19x in the Consumer Retailing industry in India. Total return to shareholders over the past year is a loss of 8.4%.お知らせ • Nov 03Sarda Proteins Ltd. to Report Q2, 2021 Results on Nov 09, 2020Sarda Proteins Ltd. announced that they will report Q2, 2021 results on Nov 09, 2020お知らせ • Aug 25Sarda Proteins Ltd. to Report Q2, 2020 Results on Sep 02, 2020Sarda Proteins Ltd. announced that they will report Q2, 2020 results on Sep 02, 2020株主還元519242IN Consumer RetailingIN 市場7D0%-3.7%-0.2%1Y-28.9%-17.0%2.4%株主還元を見る業界別リターン: 519242過去 1 年間で-17 % の収益を上げたIndian Consumer Retailing業界を下回りました。リターン対市場: 519242は、過去 1 年間で2.4 % のリターンを上げたIndian市場を下回りました。価格変動Is 519242's price volatile compared to industry and market?519242 volatility519242 Average Weekly Movementn/aConsumer Retailing Industry Average Movement6.9%Market Average Movement5.9%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.6%安定した株価: 519242の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の519242のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19912Shirish Savaliyawww.sardaproteins.comSarda Proteins Ltd.はインドで食用油と農産物の取引を行っている。マスタードオイル、マスタードオイルケーキ、大豆精製油、油糧種子、穀物、食用油などの農産物の取引を行っている。また、人材サービスも提供している。Sarda Proteins Ltdは1991年に設立され、インドのジャイプールに拠点を置く。もっと見るSarda Proteins Ltd 基礎のまとめSarda Proteins の収益と売上を時価総額と比較するとどうか。519242 基礎統計学時価総額₹921.47m収益（TTM）₹27.91m売上高(TTM)₹181.97m33.0xPER（株価収益率5.1xP/Sレシオ519242 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計519242 損益計算書（TTM）収益₹181.97m売上原価₹138.96m売上総利益₹43.01mその他の費用₹15.10m収益₹27.91m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）3.11グロス・マージン23.63%純利益率15.34%有利子負債／自己資本比率5.1%519242 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/21 04:48終値2026/08/10 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sarda Proteins Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 08Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million.Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Rights Offering
お知らせ • Jul 31+ 1 more updateSarda Proteins Limited Announces Management ChangesSarda Proteins Limited held an Extra Ordinary General Meeting on July 30, 2026. The company passed resolutions for the regularization of Mr. Gunvantray Jayantilal Zaladi (DIN: 11253353) as Non-Executive and Non-Independent Director, regularization of Mr. Shivam Gunvantray Zaladi (DIN: 11251860) as Non-Executive and Non-Independent Director, regularization of Mr. Yagnik Satasiya as Non-Executive Chairperson, and appointment of Ms. Minal Surendra Jain (DIN: 11822395) as Woman Independent Director.
Reported Earnings • Jul 18First quarter 2027 earnings released: EPS: ₹1.85 (vs ₹2.86 loss in 1Q 2026)First quarter 2027 results: EPS: ₹1.85 (up from ₹2.86 loss in 1Q 2026). Revenue: ₹184.7m (up 69% from 1Q 2026). Net income: ₹16.6m (up ₹21.5m from 1Q 2026). Profit margin: 9.0% (up from net loss in 1Q 2026). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).
お知らせ • Aug 08Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million.Sarda Proteins Ltd has filed a Follow-on Equity Offering in the amount of INR 900 million. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Rights Offering
お知らせ • Jul 31+ 1 more updateSarda Proteins Limited Announces Management ChangesSarda Proteins Limited held an Extra Ordinary General Meeting on July 30, 2026. The company passed resolutions for the regularization of Mr. Gunvantray Jayantilal Zaladi (DIN: 11253353) as Non-Executive and Non-Independent Director, regularization of Mr. Shivam Gunvantray Zaladi (DIN: 11251860) as Non-Executive and Non-Independent Director, regularization of Mr. Yagnik Satasiya as Non-Executive Chairperson, and appointment of Ms. Minal Surendra Jain (DIN: 11822395) as Woman Independent Director.
Reported Earnings • Jul 18First quarter 2027 earnings released: EPS: ₹1.85 (vs ₹2.86 loss in 1Q 2026)First quarter 2027 results: EPS: ₹1.85 (up from ₹2.86 loss in 1Q 2026). Revenue: ₹184.7m (up 69% from 1Q 2026). Net income: ₹16.6m (up ₹21.5m from 1Q 2026). Profit margin: 9.0% (up from net loss in 1Q 2026). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 11Sarda Proteins Ltd to Report Q1, 2027 Results on Jul 15, 2026Sarda Proteins Ltd announced that they will report Q1, 2027 results on Jul 15, 2026
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025)Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).
New Risk • Mar 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 420% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹722.2m market cap, or US$7.72m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m).
お知らせ • Feb 10Sarda Proteins Ltd to Report Q3, 2026 Results on Feb 14, 2026Sarda Proteins Ltd announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026
Board Change • Jan 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). MD & Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 05Sarda Proteins Ltd to Report Q2, 2026 Results on Nov 14, 2025Sarda Proteins Ltd announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Aug 12Sarda Proteins Ltd to Report Q1, 2026 Results on Aug 14, 2025Sarda Proteins Ltd announced that they will report Q1, 2026 results on Aug 14, 2025
Board Change • Aug 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jul 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jun 23Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jun 02Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • May 19Full year 2025 earnings released: EPS: ₹0.03 (vs ₹0.11 in FY 2024)Full year 2025 results: EPS: ₹0.03 (down from ₹0.11 in FY 2024). Revenue: ₹241.9m (up ₹229.0m from FY 2024). Net income: ₹51.0k (down 74% from FY 2024). Profit margin: 0% (down from 1.5% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 156 percentage points per year, which is a significant difference in performance.
お知らせ • May 13Sarda Proteins Ltd to Report Q4, 2025 Results on May 15, 2025Sarda Proteins Ltd announced that they will report Q4, 2025 results on May 15, 2025
New Risk • Mar 20New major risk - Revenue and earnings growthEarnings have declined by 5.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 5.2% per year over the past 5 years. Market cap is less than US$10m (₹215.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹241m revenue, or US$2.8m).
Board Change • Mar 03Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 13Sarda Proteins Ltd to Report Q3, 2025 Results on Jan 17, 2025Sarda Proteins Ltd announced that they will report Q3, 2025 results on Jan 17, 2025
お知らせ • Oct 26Sarda Proteins Ltd to Report Q2, 2025 Results on Nov 08, 2024Sarda Proteins Ltd announced that they will report Q2, 2025 results on Nov 08, 2024
お知らせ • Sep 11Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024, at 16:00 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2025 earnings released: ₹0.46 loss per share (vs ₹0.01 loss in 1Q 2024)First quarter 2025 results: ₹0.46 loss per share (further deteriorated from ₹0.01 loss in 1Q 2024). Net loss: ₹801.0k (loss widened ₹776.0k from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings.
お知らせ • Aug 10+ 1 more updateSarda Proteins Ltd Announces Resignation of Mahavir Pratap Sharma as Independent Director, Effective August 11, 2024Sarda Proteins Ltd. announced that the Company has received Resignation letter from Mr. Mahavir Pratap Sharma, Independent Director of the Company, informing about his resignation from the post of Independent Director of the Company due to some personal and unavoidable reason from the said position with effect from August 11, 2024.
お知らせ • Jul 31+ 1 more updateSarda Proteins Ltd Receives Resignation from Amit Kumar Modi as Company Secretary & Compliance OfficerSarda Proteins Ltd. received Resignation letter dated 31 July, 2024 from Mr. Amit Kumar Modi, Company Secretary & Compliance Officer of the Company informing about his resignation from the post of Company Secretary & Compliance Officer of the Company due to some personal and unavoidable reason with effect from the closure of business hours of 31 July, 2024.
お知らせ • Jul 17+ 1 more updateSarda Proteins Ltd Approves Board ChangesSarda Proteins Ltd. at its Board of Directors of the Company in their meeting held on 17 day of July, 2024, approved the resignation of Mrs. Vanita Bhanot from the post of Non-Executive Director, effective from July 17, 2024. The board further announced the appointment of Mr. Chintan Umeshbhai Bhatt as the Additional Director (Independent), Mr. Dhairyakumar Mohanbhai Thakkar as the Additional Director (Independent), Mrs. Dharaben Piyushkumar Patel, as the Additional Director (Non-Executive), effective from July 17, 2024. Mr. Chintan Umeshbhai Bhatt is Practicing Company Secretary. He is Associate memberof the Institute of Company Secretaries of India. He is Bachelor of Law (LL.B.), Commerce graduate (B.Com), Diploma in Tax Practice (DTP) and Diploma in Labour Practice (DLP) awarded by Gujarat University. He is having more than 4 years of experience in the field of Corporate Law and Advisory Services. Mr. Dhairyakumar Mohanbhai Thakkar is a Qualified Company Secretary from the Institute of Company Secretaries of India. He has an experience of more than 10 years in the field of Company Law matters and other corporate matters. Mrs. Dharaben Piyushkumar Patel is a commerce graduate with more than 10 years of experience in the business administration and business management. Terms of Appointment: To hold office till the upcoming Annual General Meeting of the company.
お知らせ • Jul 15Sarda Proteins Ltd Announces Resignation of Shipra Gandhi as Chief Financial OfficerSarda Proteins Ltd. has received resignation letter dated 15t July, 2024 from Mrs. Shipra Gandhi, Chief Financial Officer (CFO) of the company informing about her resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from the closure of business hours of 15th July, 2024.
お知らせ • Jun 25Sarda Proteins Ltd Appoints Khilan Hareshbhai Savaliya as Additional Director (Non-Executive)Sarda Proteins Ltd. at its board of directors meeting held on June 24, 2024, approved appointment of Mr. Khilan Hareshbhai Savaliya (DIN: 08790209) as the Additional Director (Non-Executive)' of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, with effect from 24th day of June, 2024. Terms of Appointment: To hold office till the ensuing Annual General Meetingof the company. With an experience of 3+ years in the field of Turnkey Project Management, Mr. Khilan Hareshbhai Savaliya brings a wealth of knowledge and productivity to the organization.
Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Mahavir Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 31Sarda Proteins Ltd Appoints Chirag Shantilal Thumar as Additional Executive DirectorSarda Proteins Ltd. Board of Directors of the Company in meeting held on 28 day of May, 2024, approved the appointment of Mr. Chirag Shantilal Thumar as the Additional Director (Executive) of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, effective 28th May, 2024.
Recent Insider Transactions • May 28MD & Director recently sold ₹3.0m worth of stockOn the 24th of May, Deepak Data sold around 35k shares on-market at roughly ₹84.58 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Deepak's only on-market trade for the last 12 months.
Reported Earnings • May 02Full year 2024 earnings released: EPS: ₹0.11 (vs ₹0.19 loss in FY 2023)Full year 2024 results: EPS: ₹0.11 (up from ₹0.19 loss in FY 2023). Revenue: ₹14.6m (down 75% from FY 2023). Net income: ₹194.0k (up ₹524.3k from FY 2023). Profit margin: 1.3% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Apr 22Sarda Proteins Ltd to Report Q4, 2024 Results on Apr 30, 2024Sarda Proteins Ltd announced that they will report Q4, 2024 results on Apr 30, 2024
Board Change • Feb 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.04 (vs ₹0.01 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.04 (up from ₹0.01 in 3Q 2023). Revenue: ₹10.4m (down 54% from 3Q 2023). Net income: ₹69.0k (up 306% from 3Q 2023). Profit margin: 0.7% (up from 0.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 06Sarda Proteins Ltd to Report Q3, 2024 Results on Feb 13, 2024Sarda Proteins Ltd announced that they will report Q3, 2024 results on Feb 13, 2024
お知らせ • Nov 10Sarda Proteins Ltd Announces Resignation of Somya Data as Chief Financial OfficerSarda Proteins Ltd. announced that it has received Resignation letter dated 08t November, 2023. from. Mr. Somya Data, Chief Financial Officer (CFO) of the Company informing about his resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from closure of business hours of November 30, 2023.
Reported Earnings • Nov 09Second quarter 2024 earnings released: ₹0.03 loss per share (vs ₹0.02 profit in 2Q 2023)Second quarter 2024 results: ₹0.03 loss per share (down from ₹0.02 profit in 2Q 2023). Revenue: ₹413.0k (down 99% from 2Q 2023). Net loss: ₹51.0k (down 289% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 31Sarda Proteins Ltd to Report Q2, 2024 Results on Nov 07, 2023Sarda Proteins Ltd announced that they will report Q2, 2024 results on Nov 07, 2023
お知らせ • Aug 16Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.
お知らせ • Aug 08Sarda Proteins Ltd to Report Q1, 2024 Results on Aug 14, 2023Sarda Proteins Ltd announced that they will report Q1, 2024 results on Aug 14, 2023
New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹58m revenue, or US$706k). Market cap is less than US$10m (₹79.4m market cap, or US$967.3k). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
Reported Earnings • Jun 04Full year 2023 earnings released: ₹0.19 loss per share (vs ₹1.78 profit in FY 2022)Full year 2023 results: ₹0.19 loss per share (down from ₹1.78 profit in FY 2022). Revenue: ₹59.6m (down 45% from FY 2022). Net loss: ₹331.0k (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 24Sarda Proteins Ltd to Report Q4, 2023 Results on May 30, 2023Sarda Proteins Ltd announced that they will report Q4, 2023 results on May 30, 2023
Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹55.35, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 91% over the past year.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹49.69, the stock trades at a trailing P/E ratio of 28.8x. Average trailing P/E is 30x in the Consumer Retailing industry in India. Total returns to shareholders of 51% over the past year.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹56.55, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 418% over the past three years.
Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.32 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.01 (down from ₹0.32 in 3Q 2022). Revenue: ₹22.7m (down 17% from 3Q 2022). Net income: ₹17.0k (down 97% from 3Q 2022). Profit margin: 0.1% (down from 2.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 31Sarda Proteins Ltd Announces Chief Financial Officer ChangesBoard of Directors of the Sarda Proteins Ltd, at its meeting held on, 30th January, 2023 has appointed Mr. Somya Data as the Chief Financial Officer (CFO) of the Company with effect from 01st February, 2023. Reason for Change: Due to resignation tendered by Mr. Himanshu Gupta, the Board has decided to appoint Mr. Somya Data as the Chief Financial Officer (CFO) of the company. Date of Appointment: With effect from 01st February, 2023 Qualification and Professional Experience: He is a graduate in Commerce from University of Rajasthan and is also CMA-Inter qualified from the Institute of Cost Accountants of India. He hasimmense knowledge of Financial Planning, Management of Financial Risks, Book Keeping, Financial Reporting, Indian Accounting Standards and Cost Accounting Standards.
お知らせ • Jan 24Sarda Proteins Ltd to Report Q3, 2023 Results on Jan 30, 2023Sarda Proteins Ltd announced that they will report Q3, 2023 results on Jan 30, 2023
お知らせ • Jan 20Sarda Proteins Ltd Announces Resignation of Himanshu Gupta as Chief Financial Officer, Effective 30 January 2023Sarda Proteins Ltd. announced that the company has received resignation letter dated 19 January 2023 from Mr. Himanshu Gupta, chief financial officer (CFO) of the company informing about his resignation from the post of chief financial officer (CFO) due to some personal reasons with effect from closure of business hours of 30 January 2023.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹60.35, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 453% over the past three years.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹90.90, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 41x in the Consumer Retailing industry in India. Total returns to shareholders of 732% over the past three years.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹123, the stock trades at a trailing P/E ratio of 60.4x. Average trailing P/E is 45x in the Consumer Retailing industry in India. Total returns to shareholders of 1,029% over the past three years.
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹163, the stock trades at a trailing P/E ratio of 79.8x. Average trailing P/E is 37x in the Consumer Retailing industry in India. Total returns to shareholders of 1,390% over the past three years.
Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.14 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.02 (up from ₹0.14 loss in 2Q 2022). Revenue: ₹27.9m (up 274% from 2Q 2022). Net income: ₹27.0k (up ₹266.0k from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 161% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 13Sarda Proteins Ltd to Report Q2, 2023 Results on Oct 19, 2022Sarda Proteins Ltd announced that they will report Q2, 2023 results on Oct 19, 2022
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.30, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 297% over the past three years.
お知らせ • Aug 06Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022, at 12:30 Indian Standard Time.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹32.50, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 27x in the Consumer Retailing industry in India. Total returns to shareholders of 213% over the past three years.
お知らせ • Jul 29Sarda Proteins Limited to Report Q1, 2023 Results on Aug 05, 2022Sarda Proteins Limited announced that they will report Q1, 2023 results on Aug 05, 2022
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹27.50, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 22x in the Consumer Retailing industry in India. Total returns to shareholders of 150% over the past three years.
お知らせ • May 19Sarda Proteins Limited to Report Q4, 2022 Results on May 27, 2022Sarda Proteins Limited announced that they will report Q4, 2022 results on May 27, 2022
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.32 (up from ₹0.17 loss in 3Q 2021). Revenue: ₹27.4m (up 492% from 3Q 2021). Net income: ₹560.0k (up ₹854.0k from 3Q 2021). Profit margin: 2.0% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates.
Board Change • Sep 17High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Jun 27Full year 2021 earnings released: ₹0.12 loss per share (vs ₹0.19 profit in FY 2020)The company reported a decent full year result with improved revenues, although earnings and control over costs were weaker. Full year 2021 results: Revenue: ₹114.4m (up 112% from FY 2020). Net loss: ₹202.0k (down 161% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹17.87, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 276% over the past three years.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹12.12, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 155% over the past three years.
Reported Earnings • Feb 17Third quarter 2021 earnings released: ₹0.17 loss per share (vs ₹0.56 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹4.63m (down 67% from 3Q 2020). Net loss: ₹294.0k (down 131% from profit in 3Q 2020).
お知らせ • Feb 04Sarda Proteins Ltd. to Report Q3, 2021 Results on Feb 12, 2021Sarda Proteins Ltd. announced that they will report Q3, 2021 results on Feb 12, 2021
Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 16% share price gain to ₹10.00, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 23x. This compares to an average P/E of 19x in the Consumer Retailing industry in India. Total return to shareholders over the past year is a loss of 8.4%.
お知らせ • Nov 03Sarda Proteins Ltd. to Report Q2, 2021 Results on Nov 09, 2020Sarda Proteins Ltd. announced that they will report Q2, 2021 results on Nov 09, 2020
お知らせ • Aug 25Sarda Proteins Ltd. to Report Q2, 2020 Results on Sep 02, 2020Sarda Proteins Ltd. announced that they will report Q2, 2020 results on Sep 02, 2020
